Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes

References

• American Diabetes Association Summary of revisions to the 2011 clinical practice recommendations Diabetes Care 2011 34 Suppl 1 S3 21193626
   PubMedGoogle Scholar
• Nicolucci A Rossi MC Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes Acta Biomed 2008 79 3 184 191 19260377
   PubMedGoogle Scholar
• Rodbard HW Jellinger PS Davidson JA Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on type 2 diabetes mellitus: an algorithm for glycemic control Endocr Pract 2009 15 6 540 559 19858063
   PubMed Web of Science ®Google Scholar
• Barnett AH Redefining the role of thiazolidinediones in the management of type 2 diabetes Vasc Health Risk Manage 2009 5 1 141 151
   Google Scholar
• Drucker DJ Biological actions and therapeutic potential of the glucagon-like peptides Gastroenterology 2002 122 2 531 544 11832466
   PubMed Web of Science ®Google Scholar
• Holst JJ Gromada J Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans Am J Physiol Endocrinol Metab 2004 287 2 E199 E206 15271645
   PubMed Web of Science ®Google Scholar
• Drucker DJ Nauck MA The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006 368 9548 1696 1705 17098089
   PubMed Web of Science ®Google Scholar
• Deacon CF Johnsen AH Holst JJ Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo J Clin Endocrinol Metab 1995 80 3 952 957 7883856
   PubMed Web of Science ®Google Scholar
• Triplitt CL New technologies and therapies in the management of diabetes Am J Manag Care 2007 13 Suppl 2 547 554 17927458
   PubMed Web of Science ®Google Scholar
• Baggio LL Drucker DJ Biology of incretins: GLP-1 and GIP Gastroenterology 2007 132 6 2131 2157 17498508
   PubMed Web of Science ®Google Scholar
• Drucker DJ The biology of incretin hormones Cell Metab 2006 3 3 153 165 16517403
   PubMed Web of Science ®Google Scholar
• Flatt PR Bailey CJ Green BD Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes Front Biosci 2008 13 3648 3660 18508462
   PubMed Web of Science ®Google Scholar
• Drucker DJ The role of gut hormones in glucose homeostasis J Clin Invest 2007 117 1 24 32 17200703
   PubMed Web of Science ®Google Scholar
• Triplitt C McGill JB Porte DJr Conner CS The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes J Manag Care Pharm 2007 13 9 Suppl C S2 S16 18062735
   PubMed Web of Science ®Google Scholar
• Onglyza [package insert] Princeton, NJ/Wilmington, DE Bristol-Myers Squibb Company/AstraZeneca Pharmaceuticals 2 2011
   Google Scholar
• Dickersin K Scherer R Lefebvre C Identifying relevant studies for systematic reviews BMJ 1994 309 6964 1286 1291 7718048
   PubMed Web of Science ®Google Scholar
• Jadad AR Moore RA Carroll D Assessing the quality of randomized controlled trials: is blinding necessary? Control Clin Trials 1996 17 1 1 12 8721797
   PubMedGoogle Scholar
• Augeri DJ Robl JA Betebenner DA Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J Med Chem 2005 48 15 5025 5037 16033281
   PubMed Web of Science ®Google Scholar
• Kim YB Kopcho LM Kirby MS Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118) Arch Biochem Biophys 2006 445 1 9 18 16364232
   PubMed Web of Science ®Google Scholar
• Pfützner A Paz-Pacheco E Allen E Frederich R Chen R for the CV181039 Investigators Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks Diabetes Obes Metab 2011 13 6 567 576 10.1111/j.1463-1326.2011.01385.x 21342412
   PubMed Web of Science ®Google Scholar
• Jadzinsky M Pfützner A Paz-Pacheco E Xu Z Allen E Chen R CV181-039 Investigators Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial Diabetes Obes Metab 2009 11 6 611 622 19515181
   PubMed Web of Science ®Google Scholar
• Scheen AJ Charpentier G Ostgren CJ Hellqvist A Gause-Nilsson I Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus Diabetes Metab Res Rev 2010 26 7 540 549 20824678
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Hissa MN Garber AJ for Saxagliptin 014 Study Group The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone Diabetes Care 2009 32 9 1649 1655 19478198
   PubMed Web of Science ®Google Scholar
• Göke B Gallwitz B Eriksson J Hellqvist A Gause-Nilsson I D1680C00001 Investigators Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial Int J Clin Pract 2010 64 12 1619 1631 20846286
   PubMed Web of Science ®Google Scholar
• Rosenstock J Sankoh S List JF Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes Diabetes Obes Metab 2008 10 5 376 386 18355324
   PubMed Web of Science ®Google Scholar
• Williams-Herman D Johnson J Teng R Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study Curr Med Res Opin 2009 25 3 569 583 19232032
   PubMed Web of Science ®Google Scholar
• Williams-Herman D Johnson J Teng R Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes Diabetes Obes Metab 2010 12 5 442 451 20415693
   PubMed Web of Science ®Google Scholar
• Bosi E Dotta F Jia Y Goodman M Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus Diabetes Obes Metab 2009 11 5 506 515 19320662
   PubMed Web of Science ®Google Scholar
• Derosa G Maffioli P Salvadeo SA Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients Metabolism 2010 59 6 887 895 20015525
   PubMed Web of Science ®Google Scholar
• Derosa G Maffioli P Ferrari I Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients Horm Metab Res 2010 42 9 663 669 20560108
   PubMed Web of Science ®Google Scholar
• Nauck MA Meininger G Sheng D Terranella L Stein PP Efficacy and safety of the dipeptidyl peptidase peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial Diabetes Obes Metab 2007 9 2 194 205 17300595
   PubMed Web of Science ®Google Scholar
• Ferrannini E Fonseca V Zinman B Fifty-two-week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy Diabetes Obes Metab 2009 11 2 157 166 19125777
   PubMed Web of Science ®Google Scholar
• Bolli G Dotta F Rochotte E Cohen SE Efficacy and tolerability of vildagliptin vs pioglitazone when added to metformin: a 24-week, randomized, double-blind study Diabetes Obes Metab 2008 10 1 82 90 18034842
   PubMed Web of Science ®Google Scholar
• Scott R Loeys T Davies MJ Engel SS Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes Diabetes Obes Metab 2008 10 10 959 969 18201203
   PubMed Web of Science ®Google Scholar
• Barzilai N Guo H Mahoney EM Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial Curr Med Res Opin 2011 27 5 1049 1058 21428727
   PubMed Web of Science ®Google Scholar